Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intellia Thera CS (NQ: NTLA ) 15.14 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intellia Thera CS < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > This Beaten-Down Stock Could Soar by 354%, According to Wall Street November 04, 2024 Maybe the Street is a bit too optimistic on this one. Via The Motley Fool Looking Into Intellia Therapeutics's Recent Short Interest October 29, 2024 Via Benzinga 12 High-Growth Stocks That Could Deliver Parabolic Returns October 28, 2024 These 12 innovative companies could deliver exponential returns over the next quarter century. Via The Motley Fool 7 Analysts Have This To Say About Intellia Therapeutics October 25, 2024 Via Benzinga Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today October 24, 2024 The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. Via Benzinga Topics Stocks Exposures US Equities A Closer Look at Intellia Therapeutics's Options Market Dynamics October 24, 2024 Via Benzinga 3 Health Care Stocks Moving In Thursday's Intraday Session October 24, 2024 Via Benzinga Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts September 11, 2024 Via Benzinga Why Intellia Therapeutics Stock Plummeted by 20% Today October 24, 2024 Seemingly encouraging results from the lab were met with some notable skepticism. Via The Motley Fool Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? October 24, 2024 Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses. Via Benzinga This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street October 17, 2024 Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. Via The Motley Fool 2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street October 09, 2024 These stocks haven't performed well this year. Via The Motley Fool 2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk September 29, 2024 The Ark Invest portfolio is known for taking aggressive bets. Via The Motley Fool Expert Ratings For Intellia Therapeutics August 12, 2024 Via Benzinga 3 Gene Editing Stocks with Potential to Transform Medicine August 09, 2024 Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. Via InvestorPlace NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 NTLA stock results show that Intellia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought August 01, 2024 The popular growth-stock investor added to these three existing positions on Wednesday. Via The Motley Fool 7 Biotech Stocks to Keep on Your Clinical Radar July 23, 2024 Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. Via InvestorPlace 3 Gene Editing Stocks That Could Grow Your Wealth July 17, 2024 Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. Via InvestorPlace 3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition July 17, 2024 Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. Via InvestorPlace Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday July 12, 2024 Via Benzinga 3 Profitable CRISPR Stocks Earning Analysts’ Praise July 09, 2024 Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. Via InvestorPlace The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 July 09, 2024 Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. Via InvestorPlace The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger July 09, 2024 An improbable but serious risk facing the company's investors just got minimized. Via The Motley Fool The 3 Best Gene Editing Stocks to Buy in July 2024 July 08, 2024 Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. Via InvestorPlace 3 Pharma Stocks Already Ushering in the Next Biotech Boom July 08, 2024 So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider. Via InvestorPlace The 3 Best Biotech Stocks to Buy in July 2024 July 05, 2024 For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. Via InvestorPlace Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally July 03, 2024 Via Benzinga Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today July 02, 2024 Via Benzinga 3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024 July 02, 2024 The popular growth investor is making big moves in July to bounce back after a rough start this year. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
